Table 3.
Study | Study type | Intervention | HbA1c (%) | FPG (mmol/L) | PPG (mmol/L) |
---|---|---|---|---|---|
GetGoal-Mono71 (n=361) | Efficacy in monotherapy | Lixisenatide1-step | −0.7*** | −1.1*** | −3.7*** |
Lixisenatide2-step | −0.5*** | −0.9** | −3.1*** | ||
GetGoal-F132 (n=482) | Efficacy combined with metformin (1-step versus 2-step dose increase) | Lixisenatide1-step | −0.5** | −0.53** | N/A |
Lixisenatide2-step | −0.4*** | −0.56*** | N/A | ||
GetGoal-M72 (n=680) | Efficacy combined with metformin (morning versus evening dose) | Morning lixisenatide2-step | −0.9*** | −1.19** | −4.5* |
Evening lixisenatide2-step | −0.8*** | −0.81** | NS | ||
GetGoal-S47 (n=855) | Efficacy combined with a sulfonylurea ± metformin | Lixisenatide2-step | −0.9*** | −0.99*** | −6.19*** |
GetGoal-P48 (n=484) | Efficacy combined with pioglitazone ± metformin | Lixisenatide2-step | −0.9*** | −1.16*** | N/A |
GetGoal-L Asia52 (n=311) | Efficacy with basal insulin ± sulfonylurea | Lixisenatide2-step | −0.8*** | −0.4** | −7.96*** |
GetGoal-L51 (n=496) | Efficacy with basal insulin ± metformin | Lixisenatide2-step | −0.7** | NS | −5.54*** |
GetGoal-Duo 150 (n=898) | Efficacy in combination with optimally titrated basal insulin ± OAD | Lixisenatide2-step | −0.7*** | +0.34 (NS) | −3.09*** |
GetGoal-X49 (n=634) | Head-to-head versus exenatide ± metformin (noninferiority) | Lixisenatide2-step | −0.8 | −1.22 (NS) | N/A |
Notes: All values are mean differences from baseline, significance level as compared with placebo. 1-Step, 1-Step dose increase of 10→20 μg; 2-Step, 2-Step dose increase of 10→15→20 μg.
P<0.05
P<0.005
P<0.0005. Noninferiority achieved at predefined margin of 0.4%.
Abbreviations: HbA1c, hemoglobin A1c; OAD, oral antidiabetic drug; FPG, fasting plasma glucose; PPG, postprandial glucose; NS, nonsignificant; NI, noninferior; N/A, not available.